189 related articles for article (PubMed ID: 26687836)
21. Clinicopathological and Prognostic Significance of Expression of B-Cell-Specific Moloney Murine Leukemia Virus Insertion Site 1 (BMI-1) Gene and Protein in Gastrointestinal Stromal Tumors.
Zhu K; Li K; Yuan DW; Xu G; Kang L; Dang CX; Zhang Y
Med Sci Monit; 2018 Sep; 24():6414-6421. PubMed ID: 30209248
[TBL] [Abstract][Full Text] [Related]
22. Can therapeutic drug monitoring increase the safety of Imatinib in GIST patients?
Zhuang W; Xie JD; Zhou S; Zhou ZW; Zhou Y; Sun XW; Yuan XH; Huang M; Liu S; Xin S; Su QB; Qiu HB; Wang XD
Cancer Med; 2018 Feb; 7(2):317-324. PubMed ID: 29316372
[TBL] [Abstract][Full Text] [Related]
23. Gastrointestinal stromal tumor in North Africa and the middle east: updates in presentation and management from an 11-year retrospective cohort.
Farhat F; Hussein M; Sbaity E; Alsharm A; Rasul K; Khairallah S; Assi T; Allahverdi N; Othman A; Kattan J
Hosp Pract (1995); 2023 Dec; 51(5):275-287. PubMed ID: 38112178
[TBL] [Abstract][Full Text] [Related]
24. MOZ and Menin-MLL Complexes Are Complementary Regulators of Chromatin Association and Transcriptional Output in Gastrointestinal Stromal Tumor.
Hemming ML; Benson MR; Loycano MA; Anderson JA; Andersen JL; Taddei ML; Krivtsov AV; Aubrey BJ; Cutler JA; Hatton C; Sicinska E; Armstrong SA
Cancer Discov; 2022 Jul; 12(7):1804-1823. PubMed ID: 35499757
[TBL] [Abstract][Full Text] [Related]
25. Hereditary GIST syndrome secondary to germline mutation in KIT.
Rojo E; Miranda P; Herranz R; de la Morena F
Gastroenterol Hepatol; 2023 Oct; 46(8):645-646. PubMed ID: 36634869
[No Abstract] [Full Text] [Related]
26. Survival of patients with ruptured gastrointestinal stromal tumour treated with adjuvant imatinib in a randomised trial.
Joensuu H; Reichardt A; Eriksson M; Hohenberger P; Boye K; Cameron S; Lindner LH; Jost PJ; Bauer S; Schütte J; Lindskog S; Kallio R; Jaakkola PM; Goplen D; Wardelmann E; Reichardt P
Br J Cancer; 2024 Jun; ():. PubMed ID: 38862742
[TBL] [Abstract][Full Text] [Related]
27. Metabolic pseudoprogression in a patient with metastatic KIT exon 11 GIST after 1 month of first-line imatinib: a case report.
Tassinari E; Conci N; Battisti G; Porta F; Di Scioscio V; Pirini MG; de Biase D; Nigro MC; Iezza M; Castagnetti F; Lovato L; Fanti S; Pantaleo MA; Nannini M
Front Oncol; 2023; 13():1310452. PubMed ID: 38188286
[TBL] [Abstract][Full Text] [Related]
28. Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial.
Heinrich MC; Jones RL; George S; Gelderblom H; Schöffski P; von Mehren M; Zalcberg JR; Kang YK; Razak AA; Trent J; Attia S; Le Cesne A; Siontis BL; Goldstein D; Boye K; Sanchez C; Steeghs N; Rutkowski P; Druta M; Serrano C; Somaiah N; Chi P; Reichmann W; Sprott K; Achour H; Sherman ML; Ruiz-Soto R; Blay JY; Bauer S
Nat Med; 2024 Feb; 30(2):498-506. PubMed ID: 38182785
[TBL] [Abstract][Full Text] [Related]
29. Clinical Benefit of Avapritinib in KIT-Mutant Gastrointestinal Stromal Tumors: A Post Hoc Analysis of the Phase I NAVIGATOR and Phase I/II CS3007-001 Studies.
Heinrich MC; Zhang X; Jones RL; George S; Serrano C; Deng Y; Bauer S; Cai S; Wu X; Zhou Y; Tao K; Zheng Z; Zhang J; Cui Y; Cao H; Wang M; Hu J; Yang J; Li J; Shen L
Clin Cancer Res; 2024 Feb; 30(4):719-728. PubMed ID: 38032349
[TBL] [Abstract][Full Text] [Related]
30. A phase II study on the efficacy of regorafenib in treating patients with c-KIT-mutated metastatic malignant melanoma that progressed after previous treatment (KCSG-UN-14-13).
Kim KH; Jung M; Lee HJ; Lee SJ; Kim M; Ahn MS; Choi MY; Lee NR; Shin SJ;
Eur J Cancer; 2023 Nov; 193():113312. PubMed ID: 37741071
[TBL] [Abstract][Full Text] [Related]
31. Local treatment in metastatic GIST patients: A multicentre analysis from the Dutch GIST Registry.
Brink P; Kalisvaart GM; Schrage YM; Mohammadi M; Ijzerman NS; Bleckman RF; Wal T; de Geus-Oei LF; Hartgrink HH; Grunhagen DJ; Verhoef C; Sleijfer S; Oosten AW; Been LB; van Ginkel RJ; Reyners AKL; Bonenkamp HJ; Desar IME; Gelderblom H; van Houdt WJ; Steeghs N; Fiocco M; van der Hage JA
Eur J Surg Oncol; 2023 Sep; 49(9):106942. PubMed ID: 37246093
[TBL] [Abstract][Full Text] [Related]
32. Varied presentations of gastrointestinal stromal tumour.
Kantharia CV; Irpatgire R; Prabhu RY; Bapat RD; Supe AN
Indian J Surg; 2008 Dec; 70(6):318-21. PubMed ID: 23133091
[TBL] [Abstract][Full Text] [Related]
33. Revisited analysis of a SHIVA01 trial cohort using functional mutational analyses successfully predicted treatment outcome.
Kamal M; Tarcic G; Dureau S; Edelheit O; Barbash Z; Lecerf C; Morel C; Miron B; Callens C; Servant N; Bieche I; Vidne M; Le Tourneau C
Mol Oncol; 2018 May; 12(5):594-601. PubMed ID: 29464843
[TBL] [Abstract][Full Text] [Related]
34. Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial.
Reichardt P; Demetri GD; Gelderblom H; Rutkowski P; Im SA; Gupta S; Kang YK; Schöffski P; Schuette J; Soulières D; Blay JY; Goldstein D; Fly K; Huang X; Corsaro M; Lechuga MJ; Martini JF; Heinrich MC
BMC Cancer; 2016 Jan; 16():22. PubMed ID: 26772734
[TBL] [Abstract][Full Text] [Related]
35. Impact of imatinib rechallenge on health-related quality of life in patients with TKI-refractory gastrointestinal stromal tumours: Sub-analysis of the placebo-controlled, randomised phase III trial (RIGHT).
Yoo C; Ryu MH; Nam BH; Ryoo BY; Demetri GD; Kang YK
Eur J Cancer; 2016 Jan; 52():201-8. PubMed ID: 26699729
[TBL] [Abstract][Full Text] [Related]
36. Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial.
Joensuu H; Wardelmann E; Sihto H; Eriksson M; Sundby Hall K; Reichardt A; Hartmann JT; Pink D; Cameron S; Hohenberger P; Al-Batran SE; Schlemmer M; Bauer S; Nilsson B; Kallio R; Junnila J; Vehtari A; Reichardt P
JAMA Oncol; 2017 May; 3(5):602-609. PubMed ID: 28334365
[TBL] [Abstract][Full Text] [Related]
37. Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial.
Mir O; Cropet C; Toulmonde M; Cesne AL; Molimard M; Bompas E; Cassier P; Ray-Coquard I; Rios M; Adenis A; Italiano A; Bouché O; Chauzit E; Duffaud F; Bertucci F; Isambert N; Gautier J; Blay JY; Pérol D;
Lancet Oncol; 2016 May; 17(5):632-41. PubMed ID: 27068858
[TBL] [Abstract][Full Text] [Related]
38. Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033.
Heinrich MC; Rankin C; Blanke CD; Demetri GD; Borden EC; Ryan CW; von Mehren M; Blackstein ME; Priebat DA; Tap WD; Maki RG; Corless CL; Fletcher JA; Owzar K; Crowley JJ; Benjamin RS; Baker LH
JAMA Oncol; 2017 Jul; 3(7):944-952. PubMed ID: 28196207
[TBL] [Abstract][Full Text] [Related]
39. Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.
Ben-Ami E; Barysauskas CM; von Mehren M; Heinrich MC; Corless CL; Butrynski JE; Morgan JA; Wagner AJ; Choy E; Yap JT; Van den Abbeele AD; Solomon SM; Fletcher JA; Demetri GD; George S
Ann Oncol; 2016 Sep; 27(9):1794-9. PubMed ID: 27371698
[TBL] [Abstract][Full Text] [Related]
40. The 'death pace' in the CO.17 trial.
Formica V; Formica D; Formica G
Eur J Cancer; 2016 Jan; 53():1-4. PubMed ID: 26688001
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
